Result of General Meeting

Oxford BioDynamics PLC

26 August 2026

 

26 August 2026                                        

Oxford BioDynamics Plc

("OBD" or the "Company")

Result of General Meeting and Total Voting Rights

Director/PDMR Dealings

Oxford, UK - 26 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, announces that the resolutions proposed at the General Meeting of the Company, held earlier today, pursuant to the Placing announced on 10 August 2026, were duly passed.

Accordingly, an application has been made to the London Stock Exchange for 9,150,000,000 new Ordinary Shares of £0.001 each in the capital of the Company, to be admitted to trading on AIM.

It is expected that Admission will take place, and trading in the Placing Shares will commence, at 8.00 a.m. on 27 August 2026. Following Admission, the Company's issued ordinary share capital and total voting rights will consist of 13,440,910,967 Ordinary Shares. This figure should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The total new Ordinary Shares subscribed for pursuant to the Placing by the Directors and PDMRs who are participating in the Placing, are set out below:

Director/PDMR	Existing beneficial shareholding	Placing Shares	Beneficial shareholding following the Placing	Shareholding as a percentage of the Enlarged Ordinary Share Capital
Martin Diggle1	618,542,844	500,000,000	1,118,542,844	8.32%
Richard Compton	0	300,000,000	300,000,000	2.2%
Iain Ross	23,333,333	100,000,000	123,333,333	0.9%
Dr. Alexandre Akoulitchev	14,228,962	30,000,000	44,228,962	0.3%
Paul Stockdale	6,411,252	25,000,000	31,411,252	0.2%

¹ Martin Diggle's beneficial holding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.

Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.

For further information please contact:

Oxford BioDynamics Plc Iain Ross, Non-Executive Chairman Richard Compton, CEO Paul Stockdale, CFO	[phone]
Singer Capital Markets - Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley	[phone]
OAK Securities - Joint Broker Matthew Clarke / Jerry Keen	[phone]
Camarco - Financial PR Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young	[phone] [e-mail]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)    Iain Ross 2)    Richard Compton 3)    Dr. Alexandre Akoulitchev 4)    Paul Stockdale 5)    Martin Diggle
2	Reason for the notification
a)	Position/status	1)    Non-Executive Chairman 2)    Chief Executive Officer 3)    Chief Scientific Officer 4)    Chief Financial Officer 5)    Non-Executive Director
b)	Initial notification / Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each ISIN: GB00BD5H8572
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Prices Volumes 1. £0.001 100,000,000 2. £0.001 300,000,000 3. £0.001 30,000,000 4. £0.001 25,000,000 5. £0.001 500,000,000
d)	Aggregated information	N/A - each a single transaction
e)	Date of the transaction	26 August 2026
f)	Place of the transaction	London Stock Exchange, AIM (AIMX)

 

END